Company Securities Exchange Announcements


2022 ASX Announcements
US DoD NMRC files IND application with FDA (11/05/2022)
US DoD Uniformed Services University Clinical Update (09/05/2022)
Appointment of Mr Steven Lydeamore as Chief Executive Officer (05/05/2022)
Immuron Q3 Global Sales up 216% YoY (27/04/22)
Immuron new MTEC project proposal (19/04/22)
Half Yearly Report and Accounts (25/02/22)
Response to ASX query (24/01/22)
Changes in substantial holding (24/01/22)
Immuron receives $306,154 R&D Tax Concession Refund (17/01/22)
Immuron receives European patent on Drug to treat Diarrhoea (13/01/22)
Change in substantial holding (13/01/22)
Immuron awarded $6.2 million US DoD funding for Travelan (12/01/22)
Change in substantial holding (6/01/22)
2021 and 2020 ASX Announcements
View 2021 and 2020 ASX announcements